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Abstract
Introduction: The newWHO guidelines recommend offering pre-exposure prophylaxis (PrEP) to people who are at substantial risk
of HIV infection. However, where PrEP should be prioritised, and for which population groups, remains an open question. The HIV
landscape in sub-Saharan Africa features limited prevention resources, multiple options for achieving cost saving, and epidemic
heterogeneity. This paper examines what role PrEP should play in optimal prevention in this complex and dynamic landscape.
Methods: We use a model that was previously developed to capture subnational HIV transmission in sub-Saharan Africa. With
this model, we can consider how prevention funds could be distributed across and within countries throughout sub-Saharan
Africa to enable optimal HIV prevention (that is, avert the greatest number of infections for the lowest cost). Here, we focus on
PrEP to elucidate where, and to whom, it would optimally be offered in portfolios of interventions (alongside voluntary medical
male circumcision, treatment as prevention, and behaviour change communication). Over a range of continental expenditure
levels, we use our model to explore prevention patterns that incorporate PrEP, exclude PrEP, or implement PrEP according to a
fixed incidence threshold.
Results: At low-to-moderate levels of total prevention expenditure, we find that the optimal intervention portfolios would
include PrEP in only a few regions and primarily for female sex workers (FSW). Prioritisation of PrEP would expand with
increasing total expenditure, such that the optimal prevention portfolios would offer PrEP in more subnational regions and
increasingly for men who have sex with men (MSM) and the lower incidence general population. The marginal benefit of
including PrEP among the available interventions increases with overall expenditure by up to 14% (relative to excluding PrEP).
The minimum baseline incidence for the optimal offer of PrEP declines for all population groups as expenditure increases. We
find that using a fixed incidence benchmark to guide PrEP decisions would incur considerable losses in impact (up to 7%)
compared with an approach that uses PrEP more flexibly in light of prevailing budget conditions.
Conclusions: Our findings suggest that, for an optimal distribution of prevention resources, choices of whether to implement
PrEP in subnational regions should depend on the scope for impact of other possible interventions, local incidence in population
groups, and total resources available. If prevention funding were to become restricted in the future, it may be suboptimal to use
PrEP according to a fixed incidence benchmark, and other prevention modalities may be more cost-effective. In contrast,
expansions in funding could permit PrEP to be used to its full potential in epidemiologically driven prevention portfolios and
thereby enable a more cost-effective HIV response across Africa.
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Introduction
The long-term provision of HIV treatment presents a financial
burden that is likely to approach the sum total of the national
debt of some affected countries [1]. Scaling up combination
HIV prevention is widely recognised as vital for ensuring
progress against the epidemic and alleviating this economic
burden on low- and middle-income countries. Clinical trials
have shown oral pre-exposure prophylaxis (PrEP) to be an
effective method for preventing HIV transmission [27], with
protection and adherence strongly correlated [8]. Ahead of
results from these trials, the early PrEP literature laid the
groundwork for considering the future role of PrEP and how
its introduction was expected to change the prevention
landscape [9,10]. More recently, practical issues of imple-
mentation in resource-limited countries have been discussed
[1113], and the importance of determining how best to
position PrEP within combination prevention efforts has been
emphasised [1315].
The WHO guidelines now recommend offering PrEP to
people who are at substantial risk of HIV infection [16]. What
this looks like at scale, in terms of where and how PrEP
should be implemented, comprises an open question of
immediate importance for shaping our progress toward
ambitious global goals [17]. This is particularly true for sub-
Saharan Africa, where the burden of disease is highest in the
world [18,19] and resources available for the HIV response
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are likely to remain limited [20,21]. There is thus considerable
scope for mathematical modelling to confront the complexity
of the HIV epidemic in sub-Saharan Africa and inform our
approach to PrEP implementation there.
A recent modelling study [22] evaluated the potential of a
five-year PrEP intervention targeting the general adult popula-
tion in sub-Saharan Africa. PrEP was found to be cost-effective
in countries with high HIV burdens and low rates of male
circumcision, though this was against a backdrop of homo-
geneous sexual behaviour and fixed national coverage levels
for other interventions. Anderson et al. [23] included PrEP in
the first rigorous comparison of the cost-effectiveness of
intervention portfolios across heterogeneous subnational
regions, with the scope of Kenya. We recently reported how
funds for combination prevention could be rebalanced within
and across multiple countries for a more effective continent-
wide response against HIV [24]. PrEP emerged as an important
prevention modality in this analysis, with a role in the opti-
mal prevention strategy that is complex and merits closer
examination.
Here, we use the optimal prevention strategy from our
previous work [24] as a springboard to carry out an analysis
of where, and to whom, PrEP would ideally be offered in the
resource-limited, heterogeneous setting of sub-Saharan
Africa. Our study serves as a demonstration of the principle
that widening the context in which an intervention is eval-
uated can increase both the effectiveness of that interven-
tion and the cumulative impact of combination prevention.
Methods
Model structure and prevention optimisation approach
Full details of the model structure used here, its parameters,
and their calibration to data can be found in the recent paper
by McGillen et al. [24]. For brevity, we restrict our description
to a summary of key features. At the centre of this framework
is a dynamic compartmental model that describes sexual HIV
transmission, deaths, and prevention. The model is used
to describe each top-level administrative subnational region
in 18 countries (Benin, Botswana, Burkina Faso, Cameroon,
Congo, Democratic Republic of the Congo, Ethiopia, Kenya,
Mali, Mozambique, Nigeria, Rwanda, Sierra Leone,
South Africa, Swaziland, Tanzania, Zambia, and Zimbabwe), in
total capturing 80% of the burden by people living with HIV in
sub-Saharan Africa.
In each subnational region, the population is grouped by risk
level. Key high-risk populations are female sex workers (FSW)
and men who have sex with men (MSM). The general
population includes low-risk women and men, who tend to
form stable long-term partnerships;moderate-risk women and
men, who form casual partnerships; and high-risk male clients
of sex workers. Heterosexual HIV transmission links men and
women, homosexual HIV transmission links MSM, and risk
structure further differentiates how the population groups
interact and howHIV is transmitted among and between them.
Parameters representing sexual behaviours and sexual mixing
patterns comprise the proximate determinants of risk and can
vary between these groups. After HIV infection, the model
tracks disease progression by CD4 status [25].
In [24], parameters governing biological aspects of HIV (such
as disease progression rates) were held constant across
subnational regions. For each subnational region, parameters
governing sexual behaviours, local epidemiological character-
istics, population demographics, and historical treatment and
prevention initiatives were incorporated into a standard like-
lihood expression, which was maximised using a direct-search
simplex algorithm.This produced epidemic dynamics consistent
with local data on prevalence levels [2628], prevalence trends
[29], historical circumcision levels [26], demographic character-
istics of the general population [30,31] and high-risk population
groups [3250], and historical scale-up of antiretroviral therapy
(ART) coverage [51].The calibration process was repeated for all
subnational regions (detailed fully in [24]).
Althoughdetailed data on sexual behaviours amongMSMare
available for some of Kenya’s major urban centres [52,53] and
coastal districts [54,55], these do not necessarily generalise to
other locations in sub-Saharan Africa, and data are otherwise
extremely scarce. This limits the sophistication of our represen-
tation of MSM. However, viral genotyping data indicate that
transmission betweenMSM is not isolated from transmission in
the general population [56], and studies from across Africa
suggest that 41% to 86% ofMSMhave also had sex withwomen
in their lifetime [50]. We thus assumed that all MSM can form
partnerships with both sexes, and allowed the ratio of male to
female partnerships to vary among subnational regions be-
tween a value of 1 (no preference for male partnerships) and 20
(strong preference for male partnerships).
Prevention interventions can be targeted to different popula-
tion groups to change their proximate determinants of risk and
thereby affect the cumulative incidence across population
groups. Prevention interventions considered in [24] are oral
PrEP, behaviour change communication, voluntary medical male
circumcision, and outreach testing with the offer of ART to all
HIV-positive people, which we call ‘‘early’’ ART as it typically
reaches people who are early in disease progression and would
otherwise be unlikely to present for care. In themodel, PrEP and
voluntary medical male circumcision reduce the per-partnership
probability of HIV acquisition, and behaviour change commu-
nication reduces the mean rate of changing partners. Early ART
amplifies the number of HIV-positive people on ART, reducing
onward transmission. PrEP and behaviour change communica-
tion can be offered to HIV-negative people, voluntary medical
male circumcision to uncircumcised HIV-negativemen, and early
ART to all HIV-positive people who have not already presented
for care.
We assigned unit costs to these prevention modalities in
accordance with the UNAIDS Fast Track framework [17] and
made a set of assumptions around achievable maximum
coverage levels in the population groups (Table 1). Current
coverage levels vary by subnational region for behaviour
change communication and voluntary medical male circumci-
sion, depending on historical initiatives, while early ART and
PrEP are assumed to start from the beginning of the 15-year
intervention period (2016 to 2030). In the absence of
prevention scale-up, we assume that the effects of past
behaviour change and circumcision campaigns would persist,
but early ARTand PrEP would not be introduced. In assuming a
maximum possible scaled-up PrEP coverage of 50% for the key
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populations, our model is slightly more ambitious than the
UNAIDS Fast Track, which reports an assumption of ‘‘PrEP for
30% (2030) of key populations’’ [17]. We further assume that
PrEP provides a 75% reduction in the risk of HIV acquisition
(Table 1). This effectiveness level accommodates imperfect
adherence and accords with PrEP trials that have found risk
reductions ranging from 42% (whole study arm) to 92% to 99%
(good adherers) among gay and bisexualmen and transwomen
[2] and from 62% (whole study arm) [3] to more than 90%
(good adherers) [4] among heterosexual men and women.
Previously, we used this model to set out how prevention
resources could be rebalanced across countries, and targeted
by subnational epidemiology, to enable optimally cost-
effective HIV prevention throughout sub-Saharan Africa
[24]. Our baseline-level assumption was that ART would be
provided to all HIV-positive people presenting to clinics*
typically at later disease stages*regardless of gender, risk or
location. This treatment-only scenario, together with an
assumption of constant coverage for any historical interven-
tions (such as past circumcision or behaviour change
campaigns), comprised our counterfactual for evaluating
impact. After those baseline costs were accounted for, we
used the model to estimate the effect (defined as the
number of infections averted during the intervention period
from 2016 to 2030) and cost (approximated by unit costs
multiplied by the corresponding modelled estimate of
consumption) for every possible permutation of interven-
tions and population groups in a subnational region.We then
performed an optimisation analysis to maximise the local
cost-effectiveness of these packages of targeted preventions,
under varying sets of constraints representing policy ap-
proaches. We repeated this optimisation over a range of
expenditure levels. The full model validation and resource-
optimisation analysis are detailed in [24].
Exploration of PrEP in the optimal resource distribution
Throughout this study, we focus on the role played by PrEP in
the optimal allocation of prevention resources that was set
out in our previous work [24]. As an example, we can
consider a representative net expenditure level of $20 billion
for the continent over the next 15 years (from 2016 to 2030)
and examine what role PrEP plays in scale-up of the optimal
prevention at this total expenditure. The $20 billion figure is
obtained by assuming that current levels of HIV funding [51]
will be maintained annually in the near future [21], the
prevention share in HIV spending will approach 25% [57], and
90% of this prevention share will be directed to scaling up
current methods (rather than to research and development
of new methods). As this avoids assumptions about future
domestic growth in the modelled countries and also likely
declines in HIV funding by international donors, we can
consider $20 billion to represent a moderate spending level
for the intervention period.
Retaining the costing and coverage assumptions from the
optimisation [24] (Table 1), we can see where and in which
population groups PrEP is used when the $20 billion expen-
diture is allocated optimally in our model (Figure 1). At this
expenditure, PrEP is funded for the highest risk population
groups, with FSW receiving PrEP in 63% of the modelled
regions, concentrated in southern and eastern Africa where
incidence and prevalence are high in this population group.
MSM are also at high risk, but in the absence of detailed data,
our model represents them as a more insular population and
as contributing less to onward transmission than FSW.
Consequently, they receive PrEP in fewer regions (29%) at
this expenditure level. Additionally, the available funds allow
scope for provision of PrEP to the lower incidence general
population in 12% of the modelled regions.
Table 1. Prevention interventions
Intervention Target population Effectiveness Unit cost Achievable coverage (%)
VMMC Eligible men 60% reduction in RoA $68 per procedure 80
BCC Heterosexual men 20% reduction in RoA $63 pppy 100
Low-risk women 20% reduction in RoA $63 pppy 100
FSW 50% reduction in RoA $28 pppy 100
MSM 50% reduction in RoA $28 pppy 100
Early ART Heterosexual men 70% reduction in RoT $457 pppy 33
Low-risk women 70% reduction in RoT $457 pppy 33
FSW 70% reduction in RoT $457 pppy 66
MSM 70% reduction in RoT $457 pppy 66
PrEP Heterosexual men 75% reduction in RoA $95 pppy 25
Low-risk women 75% reduction in RoA $95 pppy 25
FSW 75% reduction in RoA $95 pppy 50
MSM 75% reduction in RoA $95 pppy 50
A unit cost is assigned to each intervention following the UNAIDS Fast Track framework [17]. For continuity with previous studies [23,24], we
assume homogeneity of individual-level efficacies of early ART and PrEP with respect to risk. As this is not a forecast analysis, we do not include
discounting of costs or effects, nor do we make assumptions about whether intervention costs would decrease [61] or increase [62] with scale.
VMMC, voluntary medical male circumcision; BCC, behaviour change communication; Early ART, antiretroviral therapy as prevention comprising
outreach testing and offering of ART to all HIV-positive people; PrEP, pre-exposure prophylaxis; FSW, female sex workers; MSM, men who have
sex with men; RoA, risk of HIV acquisition; RoT, risk of onward HIV transmission; pppy, per person per year.
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Having illustrated the utility of our modelling framework
for examining where and to whom PrEP is favoured at a given
level of total prevention expenditure, we will vary this
expenditure hereafter. We start from a low expenditure level
at which very little prevention scale-up is possible ($1 million
over the 15-year period) and increase this to a level at which
all interventions can be funded in all regions ($1 trillion over
the 15-year period). Over this range, we carry out a series of
further analyses as follows.
Over the full range of prevention expenditures*that is,
from $1 million to $1 trillion over the 15-year intervention
period*we calculate the baseline HIV incidence among each
population group receiving PrEP in our model. For example,
at a given expenditure level, if PrEP is targeted to FSW in a
subnational region, we determine what the incidence among
that group would have been in 2015 in the absence of PrEP.
We repeat this calculation for all groups and expenditure
levels. For each expenditure level, we then determine the
minimum baseline incidence over the relevant subnational
regions for each group. This gives us a measure of the
minimum-incidence threshold at which PrEP is implemented
in the optimal allocation, as a function of overall prevention
expenditure.
To examine the marginal impact of PrEP in the optimal
prevention landscape, we remove PrEP from our collection of
prevention interventions and repeat our optimisation analy-
sis for the full range of total expenditure levels. This allows
the three remaining prevention mechanisms (behaviour
change communication, early ART, and voluntary medical
male circumcision) to rebalance across locations and popula-
tion groups and find a new optimal pattern in the absence of
PrEP.
Finally, we consider how the prevention landscape would
look if decisions regarding PrEP implementation were not
optimised freely, but instead were governed by an incidence
benchmark of 3 per 100 person-years, as recommended by
the new WHO guidelines [16]. To do this, we determine
which regions contain population groups with incidence
levels of at least 3 per 100 person-years in 2016, and ‘‘force’’
PrEP to be funded for those population groups in those
regions. Any population groups with incidence levels lower
than this do not receive PrEP, even if sufficient funds are
available. If funding is insufficient to provide PrEP according
to the benchmark in a given region, we allow the remaining
interventions to optimise in that region instead, as if PrEP
were not an available option in the array of interventions.
This assumes that funding is freely transferrable between
prevention modalities, rather than going unused where PrEP
is not affordable.
Results
The choice of where and for whom PrEP is funded in the
optimal prevention landscape depends partly on the in-
cidence levels of the population groups. However, the full
picture of the role played by PrEP is more intricate and rich
than a straightforward dependence on incidence. We find
that the prioritisation of PrEP also changes with the total
amount of funding available for prevention and is responsive
to the surrounding context of other favourable intervention
modalities as determined by the local epidemiology.
Other interventions are more favourable than PrEP when
resources are very limited (Figure 2). However, PrEP plays an
increasingly significant role in the optimal landscape of
combination prevention as the total expenditure increases
from $6 billion onwards, under these assumptions for unit
costs. As a function of expenditure, the interventions priori-
tised earliest are voluntary medical male circumcision and
behaviour change communication for the high-risk groups, and
early ART for the general population. These are followed at
higher expenditures by early ART for the high-risk groups, PrEP
for the high-risk groups, PrEP for the general population, and
finally behaviour change communication for the general
population. PrEP is prioritised earlier (with respect to expen-
diture) for FSW than forMSM.This is because the former group
contributesmore to onward transmission than the latter group
in our modelling framework and thus tends to be a more cost-
effective group in which to intervene.
The baseline incidence in populations receiving PrEP is not
static but decreases for all target groups as the total
prevention expenditure increases (Figure 3). Until the total
prevention expenditure reaches $6 billion, PrEP is prioritised
to MSM only in regions where this group has a very high
baseline incidence (11.3 per 100 person-years or higher) and
to FSW in regions where their baseline incidence is at least
Figure 1. Funding of PrEP by geography and population under optimal resource allocation.
Maps showing where PrEP is implemented among female sex workers (green), men who have sex with men (yellow), and the lower-risk general
population (blue), or not implemented (white), for a representative total HIV/AIDS expenditure of $20 billion in the subnational regions of our
modelled countries in sub-Saharan Africa. Grey areas are not modelled.
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4.7 per 100 person-years. However, very few regions receive
PrEP at such expenditure levels (as can be seen in Figure 2).
For expenditures above $6 billion, the minimum baseline
incidence levels among the high-risk populations receiving
PrEP decline to zero, and these groups receive PrEP in an
increasing number of regions. The general population*
which comprises low-risk women and heterosexual men
and has a lower average incidence than the highest risk
population groups*also becomes favourable for PrEP at
higher expenditures. At an expenditure of $4 billion, the
optimal prevention strategy includes PrEP for the general
population in regions where the baseline incidence is 4.1 per
100 person-years or higher. As with the key populations, this
minimum baseline incidence declines to zero as expenditure
increases. All target groups fall below the provisional WHO
incidence benchmark of 3 per 100 person-years [16] at
expenditures above $40 billion.
If we remove PrEP from the array of available prevention
modalities and optimise the implementation of the remaining
modalities, we see an overall loss of impact at moderate-to-
high expenditure levels (Figure 4), despite a rebalancing of the
other interventions in the absence of PrEP. At expenditures
below $6 billion, PrEP is used in too few places to have a
significant marginal impact, but the marginal loss of impact
due to removing PrEP increases with net prevention expendi-
ture, because PrEP is most valuable at higher expenditures
where it can be used in more places and population groups.
At maximum*that is, for a $1 trillion expenditure*PrEP
increases the impact of optimal combination prevention by
14%, and an 80% reduction on 2010 incidence is achieved by
2030, as compared to a 66% reduction without PrEP.We note
diminishing returns as this maximum expenditure is ap-
proached. This is because of saturation of the populations in
which it is possible to intervene, given our assumptions of
imperfect effectiveness and coverage levels for the interven-
tions (see Table 1).
If we enforce a provisional benchmark incidence of 3 per
100 person-years or higher [16] for PrEP implementation, and
allow the other interventions to optimise around this, the
impact pattern changes (Figure 4). At lower expenditures
(between $100 million and $6 billion), a loss of impact occurs
relative to both the fully optimal strategy and the strategy
that would be optimal in the absence of PrEP. These two
strategies are similar in this expenditure range*other
interventions are more cost-effective and hence PrEP would
be offered in very few places even if available*and the PrEP-
benchmark scenario is worse than both. At these low
expenditure levels, forcing the funding of PrEP in population
groups with incidence levels that exceed the benchmark is
costly and leaves little capacity for providing the other
interventions that would be more favourable. Higher ex-
penditures provide sufficient prevention capacity for the
impact of the benchmark-based strategy to exceed that of
the no-PrEP strategy. However, the fully optimal strategy
would give PrEP to some regions in which the target
population groups have incidence levels below the bench-
mark of 3 per 100 person-years. Without capitalising on this
opportunity for extra impact, the benchmark-based strategy
reduces incidence by up to 7% more than the no-PrEP
strategy, in contrast to the 14% marginal gain that can be
achieved by allowing PrEP to optimise freely among the other
interventions.
Figure 2. Prioritisation of PrEP among other intervention
modalities.
Percent of subnational (top-level administrative) regions in which
PrEP (black), early ART (blue), behaviour change communication
(green), and voluntary medical male circumcision (orange) are
implemented among the general population (plain curves), female
sex workers (circles) or men who have sex with men (triangles), over
a range of net prevention expenditures for the 15-year intervention
period. Female sex workers and men who have sex with men are
high-risk groups, while the general population comprises low-risk
women and heterosexual men. Voluntary medical male circumcision
can be implemented only among uncircumcised men in regions
where circumcision coverage is not already high prior to the
intervention period (40% of all regions). The x-axis is on a log scale
(mmillion, bbillion, ttrillion).
Figure 3. PrEP implementation by incidence.
Minimum baseline incidence, or minimum incidence per 100 person-
years occurring in 2015 in the absence of PrEP, in the subnational
regions where PrEP is funded for female sex workers (circles), men
who have sex with men (triangles), and the lower-risk general
population (plain curve), as a function of net prevention expenditure
over the 15-year intervention period. The horizontal line marks an
incidence of 3 per 100 person-years. The x-axis is on a log scale
(mmillion, bbillion, ttrillion).
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Discussion
Here we have considered the role of PrEP in an optimal
response to the heterogeneous epidemiology of HIV, viewing
it as one of several intervention modalities and taking the
strategic scope of sub-Saharan Africa. We have found that an
optimal prevention pattern would prioritise PrEP for high-risk
key populations, particularly FSW, across sub-Saharan Africa
at moderately high levels of total prevention expenditure.
The lower-risk general population would also receive PrEP in
some regions at higher expenditures. The choice to imple-
ment PrEP in a population group depends not only on the
incidence and overall expenditure but also on the potential
for impact of other possible interventions. This in turn
depends upon the patterns of transmission in the population
and scope for expansion of different strategies. Our analysis
has shown that an optimum strategy for combination
prevention without PrEP would be less effective over a range
of expenditure levels than one with PrEP. Moreover, the
marginal impact of PrEP would be greater at higher
expenditures, achieving a reduction on 2010 incidence levels
of up to 14% more than what is possible without PrEP.
The WHO guidelines provisionally define eligibility for PrEP
as those with an HIV incidence meeting or exceeding the
benchmark of 3 per 100 person-years in the absence of PrEP
[16]. Our model finds that, under optimal allocation of total
prevention funds, the minimum baseline HIV incidence
among populations receiving PrEP drops as the overall
expenditure increases, with all population groups receiving
PrEP at incidence levels below 3 per 100 person-years at
higher total expenditures. A strategy in which prevention is
optimised around this PrEP benchmark incurs losses in
impact for low-to-moderate expenditure levels, suggesting
that if resources are thus limited, it may be preferable to
forgo the offer of PrEP in favour of other interventions that
are less expensive for their impact. At higher expenditure
levels, the benchmark-based strategy becomes more impact-
ful than not offering PrEP. However, it also becomes less
impactful than offering PrEP in an optimal way, with losses
growing considerably as the opportunity is missed to fund
PrEP for population groups with incidence thresholds below
the benchmark. The marginal loss reaches 7% at the highest
expenditure considered here, fully half the loss that would be
incurred by not implementing PrEP at all.
Conclusions
PrEP pilot studies and demonstration projects are planned and
ongoing in several countries across sub-Saharan Africa.
Although many past modelling studies have estimated the
impact and cost-effectiveness of PrEP as an individual inter-
vention (reviewed in [58]), few have done so in the wider
context of combination prevention and none has confronted
epidemic heterogeneity both within and across multiple
countries. Our study has demonstrated how PrEP can be
used strategically to maximise impact with full consideration
of the epidemic and financial context of sub-Saharan Africa. It
is a proof-of-principle that the offer of PrEP at scale should be
guided not only by incidence in the affected populations but
also by total funding capacity and the context of other
interventions appropriate for the local epidemics. In advocat-
ing for nuanced evaluations of PrEP and other modalities for
combination prevention in resource-limited settings, this work
takes an important conceptual step toward more flexible,
epidemic-responsive, and effective HIV prevention decisions.
Because of data limitations, we have assumed that unit
costs and effect sizes are scale invariant and the same in all
countries, and that countries would not incur additional costs
by sustaining a given programme in some regions and not
others. Moreover, we have assumed that target populations
are all equally accessible, when in reality isolated areas may
be more expensive to reach than well-connected ones [59].
These factors may exaggerate the extent to which a flexible
approach to programming leads to benefits. Using a finer
geographical resolution than top-level subnational regions
may offer further insight into the relative priority of different
populations for receiving PrEP in the combination prevention
landscape. For example, a microscale case study has sug-
gested that PrEP should be prioritised first for male sex
workers, then for MSM and FSW, in Nairobi (Cremin et al.
Unpublished data). Stratification of the population by age
may also be important, particularly for young women, who
have been proposed as a priority group for PrEP implemen-
tation [60]. Differences in adherence between women aged
15 to 25 and those over 25 could, for example, raise the
relative cost of reaching the younger group. If we have
overestimated PrEP adherence here, then the marginal effect
Figure 4. Impact of optimal prevention under different strategies
for PrEP.
Percent reduction on the total HIV incidence in 2010 that can be
achieved by 2030, as a function of net prevention expenditure, for
optimal prevention allocation with PrEP (blue), without PrEP (green)
and with a benchmark incidence of 3 per 100 person-years for PrEP
implementation (red). Other prevention modalities in the optimisa-
tion are behaviour change communication, early ART, and voluntary
medical male circumcision. For very low prevention expenditures
(B$10 million), there is so little capacity for scale-up that the
epidemic rebounds slightly from its 2010 levels due to population
growth. The marginal gain from including PrEP in the optimisation
increases with prevention expenditure, with a maximum total
reduction on 2010 incidence levels of 80%, given our assumptions
around the effectiveness and coverage achievable with the inter-
ventions. The x-axis is on a log scale (mmillion, bbillion,
ttrillion).
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of PrEP has likewise been overestimated. Differences in the
modelled use of PrEP among MSM and FSW are linked to our
assumptions about the positions of these key populations in
the sexual network and the potential for the epidemic to
spread from each. As these factors are not well known in
many settings, such differences should be interpreted with
caution.
A number of extensions could be considered for this
analysis. Further insights may be gained through exploring
the sensitivity of our findings to key parameters, such as
costs and levels of coverage achievable. In particular, if PrEP
were to be less expensive relative to the other intervention
choices, we would expect it to be implemented at lower
incidence thresholds, such that it would be included in the
optimal prevention bundles for more regions and population
groups at lower levels of overall prevention expenditure.
Conversely, if PrEP were to be more expensive at scale than
what we have considered here, its role in the optimal
prevention strategy could be reduced for the amount of
prevention funding that is likely to be available in the future.
Nevertheless, if deployed selectively with consideration of
the full epidemic context, PrEP can play an important role in
the optimal prevention landscape, with its full benefits to be
realised if the coming years see a redoubling of financial
contributions to the collective fight against HIV.
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